MASSDEVICE ON CALL — Implantable defibrillators, coronary artery disease tests and implantable obesity treatment devices got the most venture capital attention in the first half of 2011, topping a list of the 10 biggest VC deals so far this year.
Coming in at number one, Cameron Health rounded up $107 million from Alloy Ventures and Delphi Ventures for its landmark completely subcutaneous implantable defibrillator, which has yet to win FDA clearance.
Following far behind in second was Intrapace Inc., which rounded up $60.9 million from InCube Ventures, L Capital Partners, and Oxford Bioscience Partners for its implantable obesity treatment system. The company won CE Mark approval in the European Union for a new wireless monitoring feature for the device earlier this month.
In third, CardioDx raised $60 million for its blood-based gene expression test for obstructive coronary artery disease.
See the full list from Fierce Medical Devices.
GE lays off 81 Milwaukee workers
GE Healthcare cut 81 positions from its Milwaukee and Waukesha, Wisc., facilities, the Milwaukee-Wisconsin Journal Sentinel reported.
Bone grafting from carpet padding
Researchers develop new scaffold for bone graft procedures made from the same foam found in everything from toys to carpet padding, WNDU Channel 16 reported.
Heart disease screening for newborns gets a push
Pulse-oximetry screening for critical congenital heart disease in newborns got an industry bump from the American Academy of Pediatrics, American College of Cardiology Foundation and American Heart Association, Heartwire reported.
Heart screening for young athletes draws more controversy
The debate continues over whether costly electrocardiograms are appropriate for young, healthy athletes should be routine, the Wall Street Journal’s Health Blog reported.